Chugai Seiyaku Kabushiki Kaisha

Sotaro Naoi

Tomoyuki Igawa

Shu Feng

Shu Wen Samantha Ho

Meiri Kawazoe

Yuki Noguchi

Toshito Nakagawa

Kazuhisa Ozeki

Takeru Nambu

Noriaki Ohminato

The present invention provides methods for detecting a complex with low affinity, under conditions in which the binding equilibrium of the complex is substantially maintained, and methods for measuring the concentration and/or amount of the complex. The invention also provides methods for evaluating the kinetics of a complex and methods for deciding on a therapeutic method that uses a pharmaceutical agent, based on the concentration and/or amount of the complex determined by the above-mentioned measurement method.

Method for detecting bi-specific antibody complex

The present invention provides a method for measuring a cellular uptake amount of a molecule, comprising (i) adding the molecule to an organ-derived cell population to perform incubation, (ii) sorting the organ-derived cell population based on the expression levels of CD31 and CD45, and (iii) after steps (i) and (ii), measuring the amount of the molecule incorporated into the cell population sorted in the step (ii), wherein the molecule is incorporated into cells via a cell surface receptor.

Method for measuring cellular uptake of molecules

The disclosure provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety and a second antigen-binding moiety, each of which is capable of binding to CD3 and CD137, but does not bind to CD3 and CD137 at the same time; and a third antigen-binding moiety that is capable of binding to DLL3, preferably human DLL3, which induce T-cell dependent cytotoxity more efficiently whilst circumventing adverse toxicity concerns or side effects that other multispecific antigen-binding molecules may have. The present invention provides multispecific antigen-binding molecules and pharmaceutical compositions that can treat various cancers, especially those associated with DLL3, by comprising the antigen-binding molecule as an active ingredient.

CD137- and DLL3-targeting multispecific antigen-binding molecules

CD3-targeting and DLL3-targeting multispecific antigen-binding molecules and uses thereof

Growing community of inventors

Shizuoka, Japan

Sotaro Naoi